Richtig, E; Loquai, C; Forschner, A; Gutzmer, R; Hassel, JC; Utikal, J; Haferkamp, S; Meier, FE; Debus, D; Dummer, R; Von Moos, RAF; Thompson, J; Gengenbacher, L; Michielin, O; Hoeller, C; Schadendorf, D.
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF(V600)-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING(MELANOMA).
J CLIN ONCOL. 2022; 40(16):-ASCO Annual Meeting; Jun 3-7, 2022; Chicago, USA.
[Poster]
Web of Science